评估Plasmodium falciparum Kelch-13突变性重组蛋白与美素之间的结合相互作用
Noorazian Md Yusuf1, Aisya Nazura Azman1,2, Amirul Adli Abdul Aziz1,3
1Parasitology Unit, Infectious Disease Research Centre, Institute for Medical Research, National Institute of Health, Shah Alam, Malaysia.
PloS one
|August 15, 2024
概括
PfK13蛋白中的单核酸多态 (SNP) 与疟疾中的艺术素抗性 (ART-R) 有关. 这项研究表明,PfK13突变改变了美素的结合,可能降低了药物的有效性,并导致ART-R.
科学领域:
- 分子生物学分子生物学
- 寄生虫学的寄生虫学
- 药物耐药性 药物耐药性 药物耐药性
背景情况:
- 疟疾治疗依赖于阿美西宁组合疗法 (ACT).
- 新兴的甲素耐药性 (ART-R) 是一个重大的公共卫生威胁.
- 在Plasmodium falciparum Kelch 13 (PfK13) 蛋白中的单核酸多态 (SNP) 与ART-R相关.
研究的目的:
- 为了产生具有特定SNP (V494I和N537I) 的复合PfK13蛋白.
- 分析这些突变的PfK13蛋白与艺术素 (ART) 的结合相互作用.
- 了解ART-R的分子基础.
主要方法:
- 复合蛋白表达和净化 (IMAC). 复合蛋白表达和净化.
- 使用SDS-PAGE和Orbitrap双重质谱法对蛋白质进行表征.
- 通过异热定位热量测量 (ITC) 和光谱测量进行约束相互作用分析.
主要成果:
- 与野生型 (WT) 相比,突变的Pfk13蛋白 (V494I和N537I) 显示出光强度的增加.
- 这表明突变的PfK13蛋白和ART之间的结合较松,表明表面蛋白暴露变化.
- 获得的蛋白质度:PfK13-WT (0.3毫克/毫升),PfK13-V494I (0.18毫克/毫升),PfK13-N537I (0.28毫克/毫升).
结论:
- PfK13突变 (V494I,N537I) 改变了与ART的结合相互作用.
- 这些变化可能导致ART有效性降低和ART-R的发展.
- 需要进一步的研究才能充分阐明ART-R的复杂机制.
更多相关视频
09:25CRISPR/Cas9 Gene Editing to Make Conditional Mutants of Human Malaria Parasite P. falciparum
Published on: September 18, 2018
9.9K
09:13Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases
Published on: November 22, 2024
1.3K
相关概念视频
01:29Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...